Understanding how certain proteins activate immune cells to fight diseases
Role of immune modulating butyrophilins in gamma delta T cell activation
This study is looking at a protein called butyrophilin 3A1 to see how it helps certain immune cells called gamma delta T cells fight infections and cancer, and it's working on new compounds that could lead to better treatments for people with immune-related health issues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Connecticut Storrs NIH-funded |
| Lab location | 1 site (Storrs-Mansfield, United States) |
| Project ID | NIH-10909956 on NIH RePORTER |
What this research studies
This research investigates the role of a specific protein, butyrophilin 3A1, in activating gamma delta T cells, which are important immune cells that respond to infections and cancer. The researchers are developing synthetic compounds that can bind to this protein to better understand how it influences immune responses. By exploring the mechanisms of this activation, the study aims to identify new therapeutic strategies for diseases that involve immune dysfunction. Patients may benefit from insights gained that could lead to innovative treatments.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include individuals with conditions that involve immune system dysfunction, such as cancer or chronic infections.
Not a fit: Patients with autoimmune diseases or those whose conditions do not involve gamma delta T cell activation may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that enhance the immune response against infections and cancer.
How similar studies have performed: Other research has shown promise in manipulating immune responses through similar mechanisms, suggesting potential for success in this area.
Where this research is happening
Storrs-Mansfield, United States
- University of Connecticut Storrs — Storrs-Mansfield, United States (Active)
Researchers
- Principal investigator: Wiemer, Andrew J — University of Connecticut Storrs
- Study coordinator: Wiemer, Andrew J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.